Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | DDX3X | O00571 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880840 | 0.86 | ALDH1A1 (0.56) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL28211599 | 0.86 | MAPT (0.57) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL29689011 | 0.85 | KMT2A (0.61) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL2010242 | 0.83 | MAPT (0.56) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL27625427 | 0.83 | MAPT (0.58) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL11118915 | 0.83 | SMN1; SMN2 (0.55) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL4611265 | 0.82 | ALDH1A1 (0.52) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL28807504 | 0.82 | MAPT (0.62) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL868793 | 0.81 | KMT2A (0.55) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 | |
| SCHEMBL12932901 | 0.81 | KMT2A (0.56) | MAPTALDH1A1ALOX12HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430967-A | High-dispersity permanent orange RN and preparation method and application thereof | 济宁阳光化学有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-1310870-C | Enantiomerically enriched 1-phenylethylamines | BAYER CHEMICALS AG (DE) | 2007-04-18 | — | — | CN | claimed |
| CN-1603302-A | Enantiomerically enriched 1-phenylethylamines | BAYER CHEMICALS AG (DE) | 2005-04-06 | — | — | CN | claimed |
| EP-0330172-B1 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER LAMBERT CO (US) | 1994-08-10 | — | — | EP | claimed |
| EP-0600045-A1 | HAIR DYE. | WELLA AG (DE) | 1994-06-08 | — | — | EP | claimed |
| WO-1993025182-A1 | HAIR DYE | WELLA AKTIENGESELLSCHAFT (DE) | 1993-12-23 | — | — | WO | claimed |
| CN-117430967-A | High-dispersity permanent orange RN and preparation method and application thereof | 济宁阳光化学有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-5260431-A | Nitroanilinesulfonic acids and the preparation of phenylenediaminesulfonic acids | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-09 | — | — | US | disclosed |
| US-5214207-A | Intermediates for reactive dyes | BASF AKTIENGESELLSCHAFT (DE) | 1993-05-25 | — | — | US | disclosed |
| EP-0515844-A1 | Phenylazo- or naphthylazobenzenes with several reactive groups | BASF Aktiengesellschaft (DE) | 1992-12-02 | — | — | EP | disclosed |
| US-5091516-A | PHENYL- OR NAPHTHYLAZOBENZENES WITH MULTIPLE REACTIVE GROUPS AND INTERMEDIATES THEREFOR | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| EP-0437699-A1 | Phenylazo- or naphthylazobenzene with several reactive groups as well as their intermediate products | BASF Aktiengesellschaft (DE) | 1991-07-24 | — | — | EP | disclosed |
| EP-0413230-A1 | Nitroaniline sulphonic acids and process for preparing phenylenediamino sulphonic acids | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
| EP-0319817-A2 | Phenylamino- and phenylaminomethyl pyridines, and hair-dyeing products containing them | Henkel Kommanditgesellschaft auf Aktien (DE) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAPT 2174/4885ALDH1A1 1263/4885ALOX12 3223/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | MAPT 2076/4885ALDH1A1 1282/4885ALOX12 3576/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAPT 2474/4885ALDH1A1 1382/4885ALOX12 2265/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | MAPT 2174/4885ALDH1A1 1263/4885ALOX12 3223/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAPT 2174/4885ALDH1A1 1263/4885ALOX12 3223/4885 |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | MAPT 1889/4885ALDH1A1 1297/4885ALOX12 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.